Retatrutide and trizepatide are a new class of medications that act on both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These combined receptor agonists demonstrate promising therapeutic efficacy in the treatment of type 2 diabetes. Retatrutide, read more a once-weekly subcutaneous injection